Back to Newsroom

Pharnext’s PXT3003 Featured in Multiple Presentations at the 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting

Paris, September 1, 2016 – Pharnext (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that data related to its lead pleodrug PXT3003, being developed for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), will be presented in four posters at the 6th international Charcot-Marie-Tooth and Related neuropathy Consortium (CMTR) conference in Venice on September 8-10, 2016.

Click here to read the full release